MX2010010343A - Inhibidores solubles en agua de molecula pequeña del regulador de conductancia transmembrana de fibrosis quistica. - Google Patents

Inhibidores solubles en agua de molecula pequeña del regulador de conductancia transmembrana de fibrosis quistica.

Info

Publication number
MX2010010343A
MX2010010343A MX2010010343A MX2010010343A MX2010010343A MX 2010010343 A MX2010010343 A MX 2010010343A MX 2010010343 A MX2010010343 A MX 2010010343A MX 2010010343 A MX2010010343 A MX 2010010343A MX 2010010343 A MX2010010343 A MX 2010010343A
Authority
MX
Mexico
Prior art keywords
compounds
water soluble
cystic fibrosis
fibrosis transmembrane
conductance regulator
Prior art date
Application number
MX2010010343A
Other languages
English (en)
Inventor
Alan S Verkman
Nitin D Sonawane
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of MX2010010343A publication Critical patent/MX2010010343A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Se proporcionan en la presente compuesto derivados de tiazolidinona altamente solubles en agua y compuestos derivados de glicina-hidrazina que inhiben la actividad del transporte iónico del regulador de conductancia transmembrana de fibrosis quística (CFTR). Los compuestos, y las composiciones que comprenden los compuestos, descritos en la presente son útiles para tratar enfermedades, trastornos, y secuelas de enfermedades, trastornos, y condiciones que están asociadas con actividad anormalmente incrementada de CFTR, por ejemplo, diarrea secretoria. Los compuestos también se pueden usar para inhibir la expansión o prevenir la formación de quistes en personas quienes tienen enfermedad de riñón poliquístico.
MX2010010343A 2008-03-25 2009-03-25 Inhibidores solubles en agua de molecula pequeña del regulador de conductancia transmembrana de fibrosis quistica. MX2010010343A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3937908P 2008-03-25 2008-03-25
US8422808P 2008-07-28 2008-07-28
PCT/US2009/038292 WO2009120803A2 (en) 2008-03-25 2009-03-25 Water soluble small molecule inhibitors of the cystic fibrosis transmembrane conductance regulator

Publications (1)

Publication Number Publication Date
MX2010010343A true MX2010010343A (es) 2010-10-15

Family

ID=40846988

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010010343A MX2010010343A (es) 2008-03-25 2009-03-25 Inhibidores solubles en agua de molecula pequeña del regulador de conductancia transmembrana de fibrosis quistica.

Country Status (9)

Country Link
US (1) US20110105565A1 (es)
EP (1) EP2279029A2 (es)
JP (1) JP2011517674A (es)
KR (1) KR20100134063A (es)
AU (1) AU2009228307A1 (es)
BR (1) BRPI0908706A2 (es)
CA (1) CA2718436A1 (es)
MX (1) MX2010010343A (es)
WO (1) WO2009120803A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA011074B1 (ru) 2004-03-30 2008-12-30 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Гидразидсодержащие соединения - ингибиторы cftr и их применение
AU2007336897A1 (en) 2006-12-22 2008-07-03 The Regents Of The University Of California Macromolecular conjugates of cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
IN2012DN00719A (es) 2009-08-10 2015-06-19 Univ California
WO2012166658A1 (en) 2011-05-27 2012-12-06 The Regents Of The University Of California Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor
FR2999191B1 (fr) * 2012-12-12 2016-02-05 Lesaffre & Cie Souches probiotiques pour le traitement et/ou la prevention de la diarrhee
CN104557764B (zh) * 2015-02-15 2017-06-16 山东大学 3,5‑二取代绕丹宁类抗凋亡蛋白Bcl‑2抑制剂及制备方法和应用
WO2016196297A1 (en) * 2015-05-29 2016-12-08 Emory University 2-amino-n'-benzylideneacetohydrazides and derivatives for the management of cftr protein mediated diseases
WO2016196303A1 (en) 2015-05-29 2016-12-08 Emory University 3-(phenyl)-n-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide compounds for the management of cftr protein mediated diseases
CN109111408B (zh) * 2017-06-26 2021-03-09 中国科学技术大学 噻唑啉酮杂环化合物、其制备方法、药用组合物及应用
US10988454B2 (en) * 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US393507A (en) * 1888-11-27 Account-book
US3280136A (en) * 1965-05-03 1966-10-18 Gen Electric 5-substituted-2, 4-oxazolidinediones and magnesium chelate intermediates therefor
JPS505260B1 (es) * 1970-09-04 1975-03-01
BE787340A (nl) * 1971-08-12 1973-02-09 Agfa Gevaert Nv Lichtgevoelig, thermisch ontwikkelbaar materiaal op basis van spectraalgesensibiliseerde organische zilverzouten
US4859228A (en) * 1987-07-16 1989-08-22 Ici Americas Inc Novel 5-aminomethylene-2,4-imidazolidinediones and 5-aminomethylene-2-thionoimidazolidine-4-ones
DE3837576A1 (de) * 1988-11-05 1990-05-10 Bayer Ag 5-carbamoyl-thiazolidine, verfahren zu ihrer herstellung und ihre verwendung als parasitizide
US5326770A (en) * 1992-07-17 1994-07-05 The Du Pont Merck Pharmaceutical Company Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals
UA56185C2 (uk) * 1996-09-30 2003-05-15 Пфайзер Інк. Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування
AU2003245555A1 (en) * 2002-06-17 2003-12-31 The Pennsylvania State Research Foundation Sphingosine kinase inhibitors
US7232573B1 (en) * 2002-09-26 2007-06-19 Advanced Cardiovascular Systems, Inc. Stent coatings containing self-assembled monolayers
US7235573B2 (en) * 2002-09-30 2007-06-26 The Regents Of The University Of California Methods of treating secretory diarrhea using cystic fibrosis transmembrane conductance regulator protein inhibitors
US20040063695A1 (en) * 2002-09-30 2004-04-01 Alan Verkman Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
NZ538809A (en) * 2002-09-30 2008-06-30 Univ California Thiazolidinone cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
WO2004093803A2 (en) * 2003-04-16 2004-11-04 Pintex Pharmaceuticals, Inc. Photochemotherapeutic compounds for use in treatment of pin1-associated states
EP1666469A4 (en) * 2003-09-11 2008-12-03 Inst Med Molecular Design Inc INHIBITOR OF INHIBITOR-1 PLASMOGENIC ACTIVATOR
EA011074B1 (ru) * 2004-03-30 2008-12-30 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Гидразидсодержащие соединения - ингибиторы cftr и их применение
JP2007063443A (ja) * 2005-08-31 2007-03-15 Tdk Corp 錯化合物及びこれを用いた光記録媒体
US20080051445A1 (en) * 2006-03-08 2008-02-28 National Institute Of Immunology. 2-Thioxothiazolidin-4-one compounds and compositions as antimicrobial and antimalarial agents targeting enoyl-ACP reductase of type II fatty acid synthesis pathway and other cell growth pathways
AU2007336897A1 (en) * 2006-12-22 2008-07-03 The Regents Of The University Of California Macromolecular conjugates of cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
JP2011516499A (ja) * 2008-04-04 2011-05-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 嚢胞性線維症膜コンダクタンス制御因子を阻害するための二価ヒドラジド化合物コンジュゲート

Also Published As

Publication number Publication date
WO2009120803A3 (en) 2009-12-30
EP2279029A2 (en) 2011-02-02
AU2009228307A1 (en) 2009-10-01
US20110105565A1 (en) 2011-05-05
JP2011517674A (ja) 2011-06-16
CA2718436A1 (en) 2009-10-01
BRPI0908706A2 (pt) 2015-07-28
KR20100134063A (ko) 2010-12-22
WO2009120803A2 (en) 2009-10-01

Similar Documents

Publication Publication Date Title
MX2010010343A (es) Inhibidores solubles en agua de molecula pequeña del regulador de conductancia transmembrana de fibrosis quistica.
WO2008079897A3 (en) Macromolecular conjugates of cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
WO2009146144A3 (en) Divalent hydrazide compound conjugates for inhibiting cystic fibrosis transmembrane conductance regulator
MX2007008555A (es) Amino-imidazolonas para la inhibicion de (-secretasa.
WO2008131000A3 (en) 7-substituted indole mcl-1 inhibitors
WO2006133426A3 (en) Compositions and methods for inhibition of the jak pathway
WO2005111039A3 (en) Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase
WO2007079164A3 (en) Protein kinase inhibitors
WO2009129335A3 (en) Selective inhibitors of histone deacetylase
WO2007129226A3 (en) Use of syk tyrosine kinase inhibitors for the treatment of cell proliferative disorders
WO2009114139A3 (en) Methods, compositions, and kits for treating pain and pruritis
MX2009009948A (es) Derivados de piridazinona utiles como inhibidores de glucano sintasa.
WO2007067781A3 (en) 9-membered heterobicyclic compounds as inhibitors of protein kinases
WO2007109178A3 (en) Indole derivatives as inhibitors of histone deacetylase
NO20072918L (no) Heteroaromatiske quinolinforbindelser, og anvendelse av disse som inhibitorer av PDE10
WO2007064872A3 (en) Urea compounds useful in the treatment of cancer
WO2007019251A3 (en) Sphingosine kinase inhibitors and methods of their use
NO20082508L (no) Aminopyrimidiner anvendelige som kinaseinhibitorer
WO2009006389A3 (en) Pyrimidine derivatives useful as raf kinase inhibitors
WO2007022384A3 (en) Pyrazine kinase inhibitors
WO2007011962A3 (en) Treatment of cancer
WO2006003388A3 (en) Compositions and methods for treating inflammatory disorders
WO2006124354A3 (en) Tyrosine kinase inhibitors
MX2009013332A (es) Inhibidores de ire-1 alfa.
WO2008076392A3 (en) Compounds useful as protein kinase inhibitors

Legal Events

Date Code Title Description
FA Abandonment or withdrawal